(function(){
			var content_array=["<p><strong>About the Study[1],[2]<br \/> <\/strong>AWARD-1 was a randomised, 52-week, placebo-controlled comparison of the effects of dulaglutide and exenatide twice-daily on glycaemic control in patients with type 2 diabetes on metformin and pioglitazone. The primary objective of the study, conducted in 978 patients, was to evaluate whether dulaglutide 1.5 mg, dosed once-weekly, was superior to placebo in reducing HbA1c from baseline at 26 weeks.<\/p>\r\n<p>To evaluate health outcomes, patients were administered questionnaires at baseline and again prior to follow-up visits at 26 and 52 weeks. Treatment satisfaction[*], as well as perceived hyperglycaemia and hypoglycaemia, were measured using the Diabetes Treatment Satisfaction Questionnaire (DTSQ); impact of weight was measured using the Impact of Weight on Self-Perception Questionnaire (IW-SP) and the Ability to Perform Physical Activities of Daily Living Questionnaire (APPADL); and perceived current health status was measured using the EuroQoL 5-Dimension Questionnaire (EQ-5D).<\/p>\r\n<p><strong>About Diabetes<br \/> <\/strong>Approximately 25.8 million Americans[3] and an estimated 371 million people[4] worldwide have type 1 and type 2 diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases. Diabetes is a chronic disease that occurs when the body either does not properly produce, or use, the hormone insulin.[5]<\/p>\r\n<p><strong>About Lilly Diabetes<br \/> <\/strong>Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and our continued commitment to providing real solutions &mdash; from medicines to support programs and more &mdash; to make lives better. For more information, visit <a rel=\"nofollow\" href=\"http:\/\/www.lillydiabetes.com\/\" target=\"_blank\">www.lillydiabetes.com<\/a>.<\/p>\r\n<p><strong>About Eli Lilly and Company<br \/> <\/strong>Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers &mdash; through medicines and information &mdash; for some of the world's most urgent medical needs. Additional information about Lilly is available at <a rel=\"nofollow\" href=\"http:\/\/www.lilly.com\/\" target=\"_blank\">www.lilly.com<\/a>. P-LLY<\/p>\r\n<p>This press release contains forward-looking statements about dulaglutide that are based on Lilly's current expectations. Actual results could differ materially from these expectations. There are significant risks and uncertainties in the process of drug development and commercialization. There can be no guarantee&nbsp;that future study results and patient experience will be consistent with the study findings to date. There can also be no guarantee that dulaglutide will be submitted to regulatory authorities in 2013, that it will receive the necessary clinical and manufacturing regulatory approvals, or that it will prove to be commercially successful. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, please see the company's latest Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Except as required by law, the company undertakes no duty to update forward-looking statements.<\/p>\r\n<p>[*]Treatment satisfaction refers to an individual's subjective appraisal of their experience of treatment (both process and outcomes), including ease of use, side effects and efficacy.[6]<\/p>\r\n<p>References<\/p>\r\n<li>Wysham      C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide versus      placebo and exenatide in type 2 diabetes (AWARD-1). Abstract #919.      Presented at the 49th European Association for the Study of Diabetes      (EASD) Annual Meeting. 23-27 September 2013, Barcelona, Spain. <\/li>\r\n<li>Van      Brunt K, Reaney M, Yu M, Lakshmanan M, Curtis B, Mitchell B. Patient-reported      outcomes with dulaglutide, exenatide, or placebo (AWARD-1) Abstract #985.      Presented at the 49th European Association for the Study of Diabetes      (EASD) Annual Meeting. 23-27 September 2013, Barcelona, Spain. <\/li>\r\n<li>Centers      for Disease Control. National Diabetes Fact Sheet-2011. Available at: <a rel=\"nofollow\" href=\"http:\/\/www.cdc.gov\/diabetes\/pubs\/pdf\/ndfs_2011.pdf\" target=\"_blank\">http:\/\/www.cdc.gov\/diabetes\/pubs\/pdf\/ndfs_2011.pdf<\/a>. Accessed on: February 22, 2012. <\/li>\r\n<li>International      Diabetes Federation. Diabetes Atlas, 5th Edition: Fact Sheet. 2012. <\/li>\r\n<li>International      Diabetes Federation. Diabetes Atlas, 5th Edition: What is Diabetes? <a rel=\"nofollow\" href=\"http:\/\/www.idf.org\/diabetesatlas\/5e\/what-is-diabetes\" target=\"_blank\">http:\/\/www.idf.org\/diabetesatlas\/5e\/what-is-diabetes<\/a>. Accessed on: February 22, 2012. <\/li>\r\n<li>Speight      J. Assessing patient satisfaction: concepts, applications and measurement.      Value in Health, 2009 8(Suppl 1):S6&ndash;S8.<\/li>\r\n<p><strong>Refer to:<\/strong> Candace Johnson, +1-317-755-9143, <a rel=\"nofollow\" href=\"mailto:johnson_candace_a@lilly.com\" target=\"_blank\">johnson_candace_a@lilly.com<\/a><\/p>\r\n<p>(Logo: <a rel=\"nofollow\" href=\"http:\/\/photos.prnewswire.com\/prnh\/20031219\/LLYLOGO\" target=\"_blank\">http:\/\/photos.prnewswire.com\/prnh\/20031219\/LLYLOGO<\/a>)<\/p>"];
			$("#dvExtra").html(content_array[0]);})();